3-羟基吡啶,2-乙氧基-(9CI) | 188670-05-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-羟基吡啶,2-乙氧基-(9CI)
• 中文别名: 2-乙氧基吡啶-3-醇
• 英文名称: 2-Ethoxypyridin-3-ol
• CAS: 188670-05-5
• 化学式: C₇H₉NO₂
• 分子量: 139.15
• InChiKey: XTGGQAFOLDDVQD-UHFFFAOYSA-N

物化性质

• 沸点：
  297.6±20.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352+P312,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P363,P403+P233,P405,P501
• 危险性描述：
  H302+H312+H332,H315,H319,H335

文献信息

• ESTROGEN MODULATORS
  申请人：Bailey Simon

  公开号：US20070149564A1

  公开（公告）日：2007-06-28

  The present application is directed to a new class of isoxazoles and their use as estrogen modulators.

  本申请涉及一种新型异噁唑类化合物及其作为雌激素调节剂的用途。
• [EN] NOVEL PROCESS<br/>[FR] NOUVEAU PROCEDE
  申请人：BIOVITRUM AB

  公开号：WO2004000829A1

  公开（公告）日：2003-12-31

  The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I). The invention also relates to (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine, hydrochloride and a process for preparing the same. Another object of the present invention is a compound of the formula (I). Another object of the present invention is a method for the treatment or prophylaxis of a serotonin-related disorder, comprising administering to a subject in need thereof an effective amount of the compound above; as well as the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

  本发明涉及一种用于制备在中枢神经系统中具有治疗活性的化合物的过程。在一个方面，本发明涉及一种制备通式（I）化合物的过程。本发明还涉及（2R）-1-（3-氯-2-吡啶基）-2-甲基哌嗪盐酸盐及其制备方法。本发明的另一个目的是一种通式（I）化合物。本发明的另一个目的是一种用于治疗或预防与5-羟色胺相关的疾病的方法，包括向需要的受试者施用上述化合物的有效量；以及利用该化合物制造用于治疗5-羟色胺相关疾病的药物。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA-CELLULAR THERAPIES INC

  公开号：WO2016154027A1

  公开（公告）日：2016-09-29

  The present invention relates to novel pyridinoxy phenylpropanamines, their pharmaceutical compositions and methods of use. In addition, the present invention relates to therapeutic methods that penetrate the blood-brain barrier and regulate the norepinephrine and serotonin transporters ("NET/SERT").

  本发明涉及新型吡啶氧基苯基丙胺、其药物组合物和使用方法。此外，本发明涉及能穿透血脑屏障并调节去甲肾上腺素和5-羟色胺转运体（"NET/SERT"）的治疗方法。
• PIPERIDINE DERIVATIVES
  申请人：Bruendl M. Michelle

  公开号：US20070142389A1

  公开（公告）日：2007-06-21

  The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R 6 and R 10 have any of the values defined therefor in the specification; pharmaceutical compositions; methods of treating conditions, diseases, and disorders; and therapeutic combinations.

  本发明提供了化合物I的公式：以及其药用盐，其中R6和R10具有规范中定义的任何值；药物组合；治疗条件、疾病和障碍的方法；以及治疗组合物。
• Novel process
  申请人：Fleck Tom

  公开号：US20060142578A1

  公开（公告）日：2006-06-29

  The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. (I)n one aspect, the invention relates to a process for the preparation of compounds of the general formula ((I)): wherein HA is a pharmaceutically acceptable acid and R 1 -R 4 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and di-C 1 -C 6 -alkylamino-C 2 -C 6 -alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

  本发明涉及一种制备在中枢神经系统中具有治疗活性的化合物的方法。(在一方面，本发明涉及一种制备具有通式(I)的化合物的方法：其中HA是一种药学上可接受的酸，R1-R4分别独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基和二C1-C6烷基氨基-C2-C6烷氧基的群。本发明还涉及使用该化合物制造治疗血清素相关疾病的药物。